

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-4 (Cancelled)

5. (Withdrawn)

6. (Withdrawn)

7. -8 (Cancelled)

9. (Currently amended) A method ~~Method~~ of treating a CD137 expressing tumor in a patient comprising administering to a patient in need thereof an effective amount of a CD137 antagonist.

10. (Currently Amended) A method ~~Method~~ according to claim 9 wherein the CD137 antagonist is selected from the group consisting of a CD137-specific antibody, a peptide, an organic small molecule, an antisense oligonucleotide, a siRNA, an antisense expression vector or a recombinant virus.

11. (Currently Amended) A method ~~Method~~ according to claim 9 wherein the tumor is a B cell lymphoma, a tumor of the vulva, a nephroblastoma, a cystadenocarcinoma of the ovary, a rhabdomyosarcoma, a leiomyosarcoma, a fibrosarcoma, an immunocytoma, a non-Hodgkin lymphoma, a carcinoma of the portio uteri or a basal cell carcinoma.

12. (Currently amended) A method ~~Method~~ according to claim 11 wherein the B cell lymphoma is chronic lymphocytic leukemia leukaemia.

13. (Withdrawn-Currently Amended) Use of CD137 or a functional analogue or derivative thereof for the preparation of a medicament A method for the

treatment of conditions a condition characterised by undesired or overactive immune responses comprising administering to a patient having a condition characterised by undesired or overactive immune response a therapeutically effective amount of a medicament comprising CD137 or a functional analogue or derivative thereof.

14. (Withdrawn-Currently Amended) Use A method according to claim 13 wherein the CD137 or functional analogue or derivative is encoded by a nucleic acid comprising a nucleotide sequence having at least 90% homology to the coding sequence shown in Fig.-8A SEQ. ID No. 1.
15. (Withdrawn-Currently amended) Use A method according to claim 14 wherein the CD137 has the amino acid sequence shown in Fig.-8B SEQ. ID No. 2.
16. (Withdrawn-Currently Amended) Use A method according to claim 13 wherein the condition is selected from an autoimmune disease, an allergy, diseases, allergies, asthma and or an organ transplant rejection.
17. (Withdrawn-Currently Amended) Use A method of an agonistic anti-CD137 ligand antibody for the preparation of a medicament for the treatment of conditions a condition characterised by an undesired or overactive immune response responses comprising admixing an agonistic anti-CD137 ligand antibody with a pharmaceutically acceptable carrier.
18. (Withdrawn-Currently Amended) Use A method according to claim 17 wherein the condition is selected from autoimmune diseases, allergies, asthma and organ transplant rejection an autoimmune disease, an allergy, asthma or an organ transplant rejection.

19. (Withdrawn-Currently Amended) A method Method for treating a patient suffering from a condition characterised by an undesired or overactive immune responses response comprising administering an effective amount of CD137 or a functional analogue or derivative thereof and/or an agonistic anti-CD137 ligand antibody.
20. (Withdrawn-Currently Amended) A method Method of claim 19 wherein the CD137 or functional analogue or derivative thereof is encoded by a nucleic acid comprising a nucleotide sequence having at least 90% homology to the coding sequence shown in Fig. 8A SEQ. ID No. 1.
21. (Withdrawn-Currently Amended) A method Method of claim 19 wherein the condition is selected from an autoimmune disease diseases, an allergy allergies, asthma and or an organ transplant rejection.
22. (Currently amended) A method Method according to claim 9 wherein the CD137 antagonist is an antibody directed to at least one epitope of the amino acid sequence of human CD137 shown in Fig. 8B SEQ. ID No. 2.
23. (Currently amended) A method Method according to claim 9 wherein the CD137 antagonist is clone BBK- 2 or clone 4B4-1
24. (Withdrawn-Currently Amended) A method Method according to claim 9 wherein the CD137 antagonist is the antisense expression vector RSV-ILA-AS.
25. (Withdrawn-Currently Amended) A method Method according to claim 9 wherein the CD137 antagonist is selected from the group consisting of a CD137 ligand-specific antibody, a peptide, an organic small molecule, an antisense

oligonucleotide, a siRNA, an antisense expression vector or a recombinant virus.

26. (Withdrawn-Currently Amended) A method Method of claim 20 wherein the CD137 has the amino acid sequence shown in Fig. 8B SEQ. ID No. 2.